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Estrogen receptor α (ER) is the major driver of ∼75% of
breast cancers, and multiple ER targeting drugs are rou-
tinely used clinically to treat patientswith ER+ breast can-
cer. However, many patients relapse on these targeted
therapies and ultimately develop metastatic and incur-
able disease, and understanding the mechanisms leading
to drug resistance is consequently of utmost importance.
It is nowclear that, in addition to estrogens, ER function is
modulated by other steroid receptors and multiple signal-
ing pathways (e.g., growth factor and cytokine signaling),
and many of these pathways affect drug resistance and pa-
tient outcome. Here, we review the mechanisms through
which these pathways impact ER function and drug resis-
tance as well as discuss the clinical implications.
Breast cancer is now the most common cancer diagnosed
in the United States, with an estimated 266,120 new
cases of invasive breast cancer to be diagnosed in women
in the United States in 2018 and an estimated 40,920
breast cancer deaths (https://www.cancer.org/content/
dam/cancer-org/research/cancer-facts-and-statistics/annual-
cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.
pdf). The lifetime risk of developing breast cancer is now
one in eight for women (Kohler et al. 2015). Approximate-
ly 75% of breast tumors are driven by the estrogen recep-
tor α (ERα; referred to here as ER)-mediated transcriptional
activity. A number of established endocrine therapies ex-
ist, including selective ERmodulators (SERMs) such as ta-
moxifen, selective ER down-regulators (SERDs) such as
fulvestrant, and aromatase inhibitors (AIs) such as letro-
zole, anastrazole (nonsteroidal AI), and exemestane (ster-
oidal AI). More recently, the targeting of cell cycle
progression with cyclin-dependent kinase 4/6 (CDK4/6)
inhibitors in combination with anti-estrogen therapy
has become the first line standard of care in de novo or re-
current metastatic disease. However, despite standard en-
docrine therapy, >20% of patients with early stage disease
develop resistance to anti-estrogens and relapse with in-
curable metastatic disease (Mauri et al. 2006; Early Breast
Cancer Trialists’ Collaborative Group [EBCTCG] 2011).
While many different mechanisms of resistance have
been described, recent data show that 11%–55% of meta-
static cancers have point mutations in the ligand-binding
domain of ER, especially in amino acids Y537 and D538,
generating a constitutively active ER that is less depen-
dent on estrogen for activity (Merenbakh-Lamin et al.
2013; Robinson et al. 2013; Toy et al. 2017). Compared
withwild-type ER,mutant ER is resistant to estrogen dep-
rivation and is less responsive to tamoxifen or fulvestrant.
This highlights the pivotal role of the ER pathway in driv-
ing breast tumor progression as well as its clinical impor-
tance in late stage disease.
The activity of wild-type ER is largely controlled by the
availability of estrogens, which bind to the ER ligand-
binding domain andmediate homodimerization and bind-
ing of the receptor complex to chromatin, usually at distal
regulatory enhancer sites. However, it is becoming in-
creasingly clear that growth factors and signaling mole-
cules from the tumor microenvironment play important
roles in the progression of ER+ breast cancer, and many
of these signaling pathways directly impact ER transcrip-
tional activity and function. This has clinical implica-
tions and suggests that targeting these pathways may
provide opportunities for the treatment of ER+ breast can-
cer patients. Here, we review the established molecular
connections between the ER and signaling pathways initi-
ated by growth factors, hormones, and cytokines from the
tumor microenvironment and discuss the clinical oppor-
tunities raised by this insight.
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Modulation of ER function by phosphorylation
Growth factors
Canonical activation of ER involves binding of estrogens
such as estradiol to the ligand-binding domain, resulting
in structural changes in ER and cofactor recruitment.
However, it is well established that post-translational
modifications such as phosphorylation, acetylation,
SUMOylation, methylation, and ubiquitination can also
modulate ER activity through multiple different mecha-
nisms (Le Romancer et al. 2011). Phosphorylation of ER
in particular is well described and plays an important
role in ER activation—in some cases, in a ligand-indepen-
dent manner (Anbalagan and Rowan 2015). The N termi-
nus of the receptor is particularly highly phosphorylated
by multiple different kinases, and these phosphorylation
events can modulate ER activity (Le Goff et al. 1994;
Kato et al. 1995; Joel et al. 1998b). Phosphorylation of
Ser118 (S118) is one of the most well-characterized ER
phosphorylation events, and phosphorylation of this resi-
due is mediated through Cdk7 upon activation of ER by
estradiol (Fig. 1; Chen et al. 2000, 2002; Harrod et al.
2017). Growth factors such as epidermal growth factor
(EGF) can also induce phosphorylation of S118 through
mitogen-activated protein kinase (MAPK), thereby acti-
vating ER independently of estrogens (Fig. 1; Kato et al.
1995; Bunone et al. 1996; Chen et al. 2002).More recently,
EGF-induced S118 phosphorylation has been suggested to
increase breast cancer cell proliferation by activating a
specific ER chromatin-binding profile through coopera-
tion with different transcription factor complexes, includ-
ing AP-1 transcription factors and the pre-B-cell leukemia
transcription factor 1 (PBX1) (Lupien et al. 2010; Magnani
et al. 2015). This implies that growth factor activation of
ER can alter the binding potential and target genes of
this transcription factor complex, and, in some cases,
this can occur in the absence of estrogen stimulation.
The recently described Y537 and D538 ER mutants are
constitutively phosphorylated on S118 by Cdk7 in an es-
trogen-independent manner, and this phosphorylation
event is likely to play an important role in regulating
the activity of the mutant receptors (Harrod et al. 2017;
Jeselsohn et al. 2018). This highlights the importance of
this phosphorylation event for ER activity and indicates
that phosphorylation of S118 may play an important
role in drug-resistant metastatic disease by potentiating
transcriptional activity of mutant ER-driven cancer. Im-
portantly, the Cdk7 inhibitor THZ1, which inhibits gene-
ral RNA polymerase II-mediated transcription (as well as
S118 phosphorylation of ER), suppresses growth in
MCF7 breast cancer cells expressing either wild-type or
mutant ER (Harrod et al. 2017; Jeselsohn et al. 2018). Al-
though THZ1 is not specific for mutant ER and instead
blocks a component of the general transcription machin-
ery, it reveals a potential avenue for pharmacological in-
tervention in patients with ER mutations.
In addition to S118, S167 is another major phosphoryla-
tion site in the N terminus of ER, which has been shown
to be important for ER-mediated transcriptional activa-
tion (Joel et al. 1998a; Becker et al. 2011; Anbalagan and
Rowan 2015). Phosphorylation of ER on this residue is in-
duced by phosphatidylinositol 3-kinase (PI3K)/AKT/
mammalian target of rapamycin (mTOR) and MAPK sig-
naling in response to hormones such as insulin, insulin-
like growth factor (IGF), and EGF (Joel et al. 1998a; Camp-
bell et al. 2001; Yamnik et al. 2009; Yamnik and Holz
2010; Becker et al. 2011; Held et al. 2012). Interestingly,
ectopic expression of AKT has been shown to redistribute
the ligand-dependent binding of ER to chromatin, presum-
ably through S167 phosphorylation of the receptor (Bhat-
Nakshatri et al. 2008), thereby further supporting the no-
tion that phosphorylation of ER can modulate receptor
binding and target gene activation.
In addition to the N terminus, the hinge region of ER
has also been shown to be phosphorylated at S305 by pro-
tein kinase-A (PKA) (Michalides et al. 2004) and Pak1 (Fig.
1; Wang et al. 2002). Phosphorylation of ER on S305 was
shown to activate the receptor in the absence of estradiol
(Wang et al. 2002) and drives receptor activity that is re-
fractory to tamoxifen inhibition (Michalides et al. 2004).
Figure 1. Activation of ER by phosphorylation induced
by growth factor and cytokine signaling pathways. Estra-
diol can induce dimerization of ER and binding of the
dimer to ER response elements (EREs) in chromatin,
and, from these sites, ER drives a proproliferative gene
program. In addition, multiple growth factor and cyto-
kine signaling pathways can induce phosphorylation of
ER at S167, S118, or S305, which can also activate the re-
ceptor and drive it onto chromatin in the absence of es-
tradiol, thereby promoting cell proliferation.
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Using a phospho-specific antibody for transcription factor
mapping (chromatin immunoprecipitation [ChIP] fol-
lowed by deep sequencing [ChIP-seq]) analysis, PKA-me-
diated ER phosphorylation on S305 has been suggested
to induce receptor binding to a distinct set of binding sites
that are not typically seen following estradiol-induced ER
binding, implying that these are nonclassic regulatory
sites. It was suggested that this mechanism can mediate
tamoxifen resistance, partly through expression of the on-
cogene c-MYC (de Leeuw et al. 2013). Together, this dem-
onstrates that phosphorylation of ER can modulate
receptor binding and activity in a ligand-independent
and nonclassical manner.
Cytokines
The tumor microenvironment is composed of a complex
ensemble of cell types, including fibroblasts, fat cells,
and immune cells such as macrophages, neutrophils,
and T cells (Artacho-Cordon et al. 2012). These cells
play an important role in breast cancer progression. As
an example, Finak et al. (2008) identified a gene signature
from the stromal compartment of breast cancer patients
that predicts outcome independent of other tumor mark-
ers such as ER and HER2. Paracrine signaling is likely to
be the major mechanism through which stromal cells af-
fect tumor cell function, as stromal cells secrete a variety
of signaling molecules, including hormones and inflam-
matory cytokines, many of which have been shown to
be associated with tumor progression in breast cancer pa-
tients, where they impinge on the function and phenotype
of cancer epithelial cells. For example, coculture of fibro-
blasts with breast cancer cells has been shown to decrease
expression of ER in the cancer cells (Brechbuhl et al. 2017;
Huang et al. 2017; Morgan et al. 2018) and activate potent
growth factor pathways (e.g., AKT and MAPK), thereby
modulating the response of the epithelial cancer cells to
anti-estrogen treatment (Brechbuhl et al. 2017; Huang
et al. 2017). Furthermore, the adipokines leptin and inter-
leukin-6 (IL-6) have been shown to be associated with in-
creased tumor size and metastasis in ER+ breast cancer
patients (Madeddu et al. 2014). However, the molecular
mechanisms underlying potentially causal effects of
paracrine signaling from the stromal cells in the tumor
microenvironment on breast cancer progression are only
starting to emerge and appear to involve modulation of
ER action through different mechanisms (see also “Redi-
rection of ER Function by Transcription Factors Down-
stream from Hormone and Cytokine Signaling”).
It has been shown recently that the cytokines tumor ne-
crosis factor α (TNFα) and IL-1β, which can be produced by
multiple different cell types, including immune cells such
as macrophages, can induce phosphorylation of S305 on
ER (Stender et al. 2017). Cytokine-induced phosphoryla-
tion of this residue is mediated by inhibitor of nuclear fac-
tor κ B kinase subunit β (IKKβ), rather than PKA or Pak1
(which have been shown previously to phosphorylate
S305). Cytokine-induced S305 phosphorylation of ER re-
sults in ER binding to a subset of binding sites typically
seen following estradiol induction, and the target genes
regulated by cytokine-induced phosphorylation of S305
represent a subset of estradiol-induced genes (Stender
et al. 2017). Importantly, the cytokine-induced gene pro-
gram in MCF7 breast cancer cells can induce extravasa-
tion, an important part of the metastatic process, and
this occurs through ER but independently of estradiol
(Stender et al. 2017). Consistently, overexpressing a con-
stitutive active form of IKKβ, which is a key kinase down-
stream from TNFα, increases invasion in vitro and in vivo
in the presence of estradiol (El-Shennawy et al. 2018). In-
terestingly, MCF7 breast cancer cells also become resis-
tant to tamoxifen in the presence of these cytokines,
showing that extracellular stimuli, in the form of specific
cytokines, can modulate drug responsiveness.
Transforming growth factor β (TGFβ) is another cyto-
kine secreted by cancer cells as well as stromal cells in
the tumor microenvironment such as fibroblasts and im-
mune cells (e.g., macrophages and leukocytes) and is
known to play an important role in tumor progression in
manydifferent cancer types (Papageorgis and Stylianopou-
los 2015). TGFβ appears to have a dual function, where it
represses early tumor growth but promotes metastasis in
late stage disease. This takes place both through direct ef-
fects on the tumor cells (e.g., TGFβ can induce epithelial-
to-mesenchymal transition [EMT]) (Deckers et al. 2006)
and by modulating the tumor microenvironment (e.g., by
inducing an immunosuppressive environment) (Papageor-
gis and Stylianopoulos 2015). Canonical TGFβ signaling
induces phosphorylation of the transcription factors
SMAD2 and SMAD3, which then associate with SMAD4
to activate TGFβ target genes. TGFβ signaling inhibits
ER function in a SMAD4-dependent manner (Wu et al.
2003; Ren et al. 2009). Consistent with a repressive func-
tion of SMAD4 on ER function, the association between
these proteins is induced by anti-estrogens such as tamox-
ifen (Wu et al. 2003). In the absence of SMAD4, activation
of SMAD3 by TGFβ enhances ER activity (Wu et al. 2003;
Ren et al. 2009). Thus, although the precise mechanisms
through which these SMADs regulate ER activity are not
clear, these findings indicate thatTGFβ signaling regulates
breast cancer progression at least partly by directly regu-
lating ER function. Furthermore, ER also inhibits TGFβ
signaling, which is likely to be another important mecha-
nism through which cross-talk between these pathways
regulates breast cancer progression (Band and Laiho 2011).
Taken together, this illustrates the potential power of
cytokine secretion from cells in the tumor microenviron-
ment to alter ER activity and endocrine responsiveness in
breast cancer. It also suggests that targeting these path-
ways may provide novel approaches for treating resistant
ER+ breast cancer. Validating these mechanisms in vivo
and in patient samples will be an important next step to
investigate the translatability of these findings.
Effect of drugging growth factor and cytokine pathways
in ER+ breast cancer
The PI3K/AKT/mTOR pathway is commonly mutated in
both primary and recurrent ER+ breast cancer (The Cancer
Estrogen receptor cross-talk in cancer
GENES & DEVELOPMENT 1143
 Cold Spring Harbor Laboratory Press on May 9, 2019 - Published by genesdev.cshlp.orgDownloaded from 
Genome Atlas Network 2012; Ciruelos Gil 2014; Yates
et al. 2017) and regulates activation of ER through phos-
phorylation as described above, and activation of this path-
way can lead to acquired endocrine resistance (Campbell
et al. 2001; Vivanco and Sawyers 2002; Miller et al. 2010;
Sanchez et al. 2011; Cavazzoni et al. 2012). Consequently,
drugs directed against these pathways have been assessed
in clinical trials in combination with ER targeting com-
pounds. Preclinical data in a breast cancer cell line andmu-
rine xenograft models demonstrating anti-proliferative
effects of these drugs suggest that this approach is viable
(Boulay et al. 2005; Crowder et al. 2009; Ghayad et al.
2010; Guichard et al. 2015).
EGFR inhibitors The utility of the EGFR tyrosine kinase
inhibitors (TKIs) gefitinib and lapatinib, in combination
with endocrine therapy for the management of de novo
or recurrentmetastatic breast cancer, has been investigat-
ed in both the first and second line setting in four separate
studies.With the exceptionof one study (Cristofanilli et al.
2010), no significant progression-free survival (PFS) im-
provements have been reported with EGFRTKIs (Osborne
et al. 2011; Carlson et al. 2012; Burstein et al. 2014). Para-
doxically, in the small phase II study where a PFS benefit
was observed (Cristofanilli et al. 2010), the objective re-
sponse rate was numerically lower with the EGFR TKI
plus AI combination (2%) compared with the AI plus pla-
cebo (12%), further indicating that endocrine resistance
is not delayed by EGFR inhibition.
mTOR inhibitors Inhibition of the mTOR pathway has
received substantial attention in recent years, due to the
development of inhibitors and the preclinical data func-
tionally linking mTOR activity in ER+ disease. Clinical
trial evidence culminated in the approval of everolimus
(an inhibitor of the mTOR complex 1) in combination
with exemestane for the treatment of nonsteroidal AI-re-
sistant metastatic ER+ breast cancer. In the BOLERO-2
study, a double-blind phase III trial (Yardley et al. 2013),
investigator-assessed PFS (the primary end point) was
more than doubled with the addition of everolimus alone
(7.8 mo for everolimus compared with 3.2 mo for placebo;
hazard ratio [HR] 0.45; 95% confidence interval [CI];
0.38–0.54). However, median overall survival (OS) was
not significantly improved when everolimus was com-
bined with exemestane: 31 mo compared with 26.6 mo
with placebo plus exemestane (HR 0.89; 95% CI; 0.73–
1.10; P = 0.14) (Piccart et al. 2014). The phase 2 BOLERO-
4 study then explored the utility of combining everolimus
with an AI as first line treatment for ER+ HER2− advanced
cancer, yielding a median PFS of 22.0 mo (95% CI; 18.1–
25.1 mo) (Royce et al. 2018). While this is potentially im-
pactful, cross-trial comparisons with studies of newer
therapeutics, such as CDK4/6 inhibitors, in combination
with AIs can be made only cautiously due to the single-
armopen-label designof theBOLERO-4 study. Interesting-
ly, retrospective evidence has now established the use of
everolimus and exemestane as second line therapy follow-
ing progression on CDK4/6 inhibitors plus AIs—the now
established first line therapy for metastatic ER+ HER2−
metastatic breast cancer (Dhakal et al. 2018).
AKT inhibitors Given that AKT has been shown to acti-
vate ER through phosphorylation of S167 (Campbell et al.
2001) and that increased AKT activity is found in 20%–
55% of breast cancers (Altomare and Testa 2005), which
is associated with reduced OS in patients with ER+ cancer
treated with tamoxifen (Kirkegaard et al. 2005), the im-
pact of targeting AKT is also being explored. Preclinical
evidence for combining AIs and AKT inhibitors in anas-
trozole-resistant cancer cells (Vilquin et al. 2013) has
lead to the initiation of a clinical trial using this combina-
tion in the AI-resistant setting (NCT01344031) (Ma et al.
2016). Other novel AKT inhibitors such as AZD5363
(Banerji et al. 2018) are in early phase clinical trials.
PI3K inhibitors Clinical trials assessing the pan-class 1
PI3K inhibitors buparlisib (BKM120) and pictilisib (GDC-
0941) were limited by prohibitive dose-limiting toxicity
and lack of efficacy, resulting in marginal PFS benefits in
a cohort of AI-pretreated post-menopausal women with
metastatic breast cancer (Krop et al. 2016; Baselga et al.
2017). More promisingly, the α-specific PI3K inhibitors
alpelisib (BYL719) and taselisib (GDC-0032) have demon-
stratedefficacy in early phase trials and shownmodest tox-
icity. While the results of the placebo-controlled phase III
SOLAR-1 trials evaluating the potential improvement
in PFS with the addition of alpelisib to fulvestrant
(NCT02437318) among patients with ER+ metastatic
breast cancer are awaited, results from the SANDPIPER
trial using taselisib have now been reported (Baselga
et al. 2018). A PFS benefit of only 2 mo was observed
with the combination of taselisib plus fulvestrant (7.4
mo), compared with placebo plus fulvestrant (5.4 mo) in
a population of patients harboring PIK3CA mutations
(HR 0.7; P= 0.0037). In addition, this small benefit came
at the expense of significant toxicity, with 32%of patients
experiencing serious adverse events. The concept of tar-
geting PIK3CA remains critically important, but recent
data highlight the need to developmore α-specific targeted
agents tomaximally exploit this combination.Additional-
ly, resistance to these α-specific inhibitors through acqui-
sition of mutations in PTEN have already been described
(Juric et al. 2015), potentially further limiting the clinical
utility of these drugs.
Mechanism of action of PI3K/AKT/mTOR targeting
drugs The finding that someof the PI3K/AKT/mTOR in-
hibitors described above showefficacy inER+breast cancer
has increased focus on the underlying mechanism of ac-
tion. The fact that the PI3K/AKT/mTOR pathway has
been shown to regulate ER activity directly through phos-
phorylation as described above raises the question of
whether PI3K/AKT/mTOR targeting drugs inhibit tumor
growth by directlymodulating ER activity. Unexpectedly,
in preclinical models, the α-specific PI3K inhibitor alpeli-
sib was found to redistribute chromatin binding of the
ER complex, thereby increasing ER activity (Toska et al.
Siersbæk et al.
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2017), in stark contrast to what would be predicted from
inhibition of an activating PI3K pathway. In contrast to
this finding, we showed recently that the two mTOR in-
hibitors everolimus (inhibitor of mTOR complex 1) and
vistusertib (AZD2014; inhibitor of mTOR complexes 1
and 2) do not affect binding of ER to chromatin despite ro-
bust inhibition of themTOR pathway. This indicates that
these drugs likely function through an ER-independent
mechanism to control tumor growth. Indeed, this is con-
sistent with findings from the BOLERO-3 study (Andre
et al. 2014) and subsequent BOLERO-1 study (Hurvitz
et al. 2015), where benefit from everolimus, when com-
bined with trastuzumab (HER2 monoclonal antibody)
and chemotherapy in HER2-positive breast cancer pa-
tients, was, in fact, observed to be greater in ER-negative
patients compared with ER+ patients. This questions the
direct impact of mTOR inhibition on ER transcriptional
activity in ER+ disease.
Taken together, this raises two important points. First,
given that many of the drugs targeting the PI3K/AKT/
mTOR pathway show some efficacy in ER+ breast cancer,
it is critical to delineate the precise mechanisms through
which these drugs inhibit tumor growth. An essential
part of this is to clarify whether these inhibitors genuinely
modulate ER activity or are general cell cycle regulatory
compounds. This information is required for rational de-
sign of combinatorial strategies to treat ER+ breast cancer
patients. Second, due to the generally modest clinical
efficacy of assessed PI3K/AKT/mTOR targeting drugs,
it is important to evaluate the role and clinical utility
of PI3K/AKT/mTOR inhibition compared with newer
treatment modalities, such as CDK4/6 inhibition, that
are rapidly altering the treatment landscape for ER+ breast
cancer.Currently, besidePIK3CAmutational status (May-
er et al. 2017; Baselga et al. 2018), nobiomarkers areused in
the clinic to stratify patients to receive inhibitors of the
PI3K/AKT/mTOR pathway, and attempts to identify
such biomarkers have had limited success (Chandarlapaty
et al. 2016; Hortobagyi et al. 2016). A significant require-
ment for maximal exploitation of PI3K/AKT/mTOR
inhibitors is therefore the identification of specific bio-
markers that are predictive of response to these
compounds.
Cytokine pathway inhibitors The potential for targeting
cytokine pathways therapeutically is highlighted by a
wealth of preclinical evidence supporting the capacity
for cytokine secretion to not only promote growth, prolif-
eration, andmetastatic potential but also alter ER activity
and endocrine responsiveness.
For example, given that activation of the nuclear factor
κB (NF-κB) pathwayhasbeen implicated inendocrine resis-
tance and poor outcomes in ER+ breast cancer (Oida et al.
2014), the role of combining anti-NF-κB and endocrine
therapy has been explored. Bortezomib, a proteasome in-
hibitor that blocks theNF-κBpathway,was added to either
an AI or tamoxifen in a small single-arm phase II study to
investigatewhether endocrine responsiveness could be re-
established in a cohort of relapsed patients with progres-
sive and measurable disease (Trinh et al. 2012). While no
objective responses were observed, a clinical benefit rate
of 22% was reported; however, this came at the expense
of significant gastrointestinal toxicities.
Accumulating evidence also suggests that inhibition of
the receptor activator ofNF-κB ligand (RANKL), which ac-
tivates the NF-κB pathway, not only increases bone mass
and strength but also has anti-tumor effects. Preclinically,
RANKL inhibition decreases mammary carcinogenesis
and reduces metastatic tumor burden in bone and other
tissues (deGroot et al. 2018). Denosumab, an antibody tar-
geting RANKL, is licensed to treat osteoporosis and pre-
vent skeletal-related events in patients with breast
cancer bone metastases (Gnant et al. 2015) and has been
shown recently to improve disease-free survival in pa-
tients (Gnant et al. 2018). Conversely, however, in the re-
cently reported D-Care study, adjuvant denosumab failed
to reduce rates of breast cancer recurrence or death in
higher-risk patients receiving optimal loco-regional and
“standard of care” systemic adjuvant therapy (Coleman
et al. 2018).
Overall, these early signs of activity indicate that explo-
ration of inhibition of cytokine pathways in ER+ breast
cancer patients warrants further clinical investigation.
Redirection of ER function by transcription factors
downstream from hormone and cytokine signaling
It has been demonstrated in breast cancer patient samples
that differential binding profiles for ER are associatedwith
clinical outcome (Ross-Innes et al. 2012). It has been hy-
pothesized that the differential ER genomic binding pat-
terns dictate activation of distinct target genes that are
associated with treatment response. This highlights the
functional importance of ER–chromatin interactions for
tumor progression and the need for delineating the factors
and pathways that influence ER binding to chromatin.
ER functions as part of a large transcriptional complex
involvingmultiple transcription factors, including its pio-
neer factor, FOXA1 (Hurtado et al. 2011), as well as other
cooperating factors; e.g., PBX1 (Magnani et al. 2011), the
transcription factor AP-2γ (Tan et al. 2011), and GATA-
binding protein 3 (GATA3) (Theodorou et al. 2013).
Many of these modulate the activity of the ER pathway
by directly affecting binding of ER to chromatin; e.g., by
modulating the local accessibility of the chromatin, as
has been suggested for FOXA1 (Hurtado et al. 2011) and
PBX1 (Magnani et al. 2011, 2015).
The finding that multiple cytokines and hormones are
associatedwith the outcome in ER+ breast cancer suggests
that the downstream effectors of these stimuli may also
modulate ER function. Indeed, it has been shown that a
cocktail of cytokines and growth factors, including IL6,
TNFα, IGF-1, and EGF, can redistribute binding of ER
and its pioneer factor, FOXA1, to different sites even in
the presence of estrogen (Ross-Innes et al. 2012). This sug-
gests that the cytokine/hormone-induced redistribution
of ER bindingmay contribute to altered transcriptional ac-
tivity and therefore may play a functional role in tumor
progression.
Estrogen receptor cross-talk in cancer
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TNFα-mediated redistribution of ER binding
through NF-κB
The role of TNFα in modulating ER binding to chromatin
has been characterized recently in more detail at selected
loci (Pradhan et al. 2012) and genome-wide (Franco et al.
2015). TNFα signaling drives phosphorylation and subse-
quent degradation of the repressor IκB, which releases
the transcription factor complex NF-κB, which subse-
quently translocates to the nucleus and binds to target re-
gions in chromatin (Hayden and Ghosh 2008). TNFα
signaling has been shown to inhibit breast cancer cell pro-
liferation induced by estradiol both in vitro and in vivo.
Franco et al. (2015) showed that activation of NF-κB by
TNFα redirects ER to a subset of NF-κB-binding sites,
and this leads to increased production of noncoding en-
hancer RNA (eRNA) transcripts from these sites, which
has been linked previously to enhancer activation by ER
(Fig. 2A; Hah et al. 2013; Li et al. 2013; Lam et al. 2014).
Importantly, this increase in enhancer activity is associat-
ed with activation of nearby protein-coding genes, which
are associated with clinical outcome in breast cancer pa-
tients (Franco et al. 2015). This indicates that targeting
of this pathway may have therapeutic potential. This
mechanism of cooperativity between NF-κB and ER is
consistent with detailed molecular analysis of the baculo-
viral inhibitor of apoptosis (IAP) repeat-containing 3
(BIRC3) target gene, showing that TNFα-induced binding
of NF-κB to the BIRC3 promoter primes it for ER binding,
which in turn potentiates TNFα-induced activation of
BIRC3 (Pradhan et al. 2012). Taken together, this illus-
trates how signaling molecules from the tumor microen-
vironment can ultimately activate new enhancers and
target genes in the tumor cells by co-opting ER function.
Although TNFα can activate ER by phosphorylation in
the absence of ER ligand, redistribution of ER binding to
new enhancers by TNFα has been demonstrated only in
the presence of estrogen-liganded ER (Franco et al. 2015;
Stender et al. 2017). It is currently unclear whether NF-
κB can redistribute tamoxifen-bound ER and whether ER
will occupy these new NF-κB-primed ER-binding sites in
response to TNFα in the absence of estrogens (e.g., in
breast cancer patients successfully treated with AIs).
However, some patients relapsing on AIs will have a
A
B
Figure 2. Redistribution of ER chromatin binding by
other transcription factors. (A) Redistribution of ERbind-
ing to chromatin by progestogens and the cytokineTNFα
through activation of progesterone receptor (PR) andNF-
κB, respectively. (B) Modulation of ER binding and activ-
ity by glucocorticoids through activation of glucocorti-
coid receptor (GR).
Siersbæk et al.
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functional ER pathway, such as those with the Y537 and
D538 mutations in the ligand-binding domain of ER,
which renders the receptor constitutively active (Robin-
son et al. 2013). It will be important to determinewhether
binding of mutant ER is also redistributed by TNFα,
which would indicate that TNFα might also regulate ER
function in the metastatic setting.
Cross-talk between ER and other steroid hormone
receptors
Progesterone receptor (PR) Although ER is the driving
transcription factor in ER+ breast cancer, other steroid re-
ceptors have been shown to affect tumor progression by
modulating ER function—most notably the PR, which is
expressed in ∼75% of ER+ breast cancer. PGR is a classical
ER target gene (Horwitz and McGuire 1978), and PR ex-
pression therefore has been used historically as a bio-
marker of an active ER pathway, which is predictive of
patient outcome (Blows et al. 2010; Purdie et al. 2014).
However, it is becoming increasingly clear that PR plays
a more direct functional role in controlling progression of
established tumors. Progestogens (i.e., natural and syn-
thetic compounds that activate PR) have been shown in
multiple studies to inhibit breast tumor growth in both
preclinical models and patients (for review, see Carroll
et al. 2017). More recently, our laboratory described the
mechanism underlying the inhibitory effect of progesto-
gens on tumor growth. This involves PR-directed redistri-
bution of ER to PR-binding sites through an ER response
element (ERE)-independent mechanism involving tether-
ing of ER to chromatin through PR (Fig. 2A; Mohammed
et al. 2015). This effectively sequesters ER away from its
proproliferative gene targets, thereby inhibiting growth.
This indicates that redirecting ER binding around the ge-
nome by progestogensmay provide amechanism to inhib-
it ER function in breast cancer (Carroll et al. 2017), which
may be effective both in combinationwith SERMs, as sug-
gested by preclinical xenograft experiments (Mohammed
et al. 2015), and in tamoxifen-resistant cancer cells
(Vignon et al. 1983).
Clinical benefit has been demonstrated from a single in-
jection of progesterone administered before surgery
(Badwe et al. 2011), and the use of a single agent, progesto-
gen, has been consistently shown to clinically benefit
patients as either first line therapy in de novo metastatic
ER-positive breast cancer or in advanced disease when
ER targeted endocrine agents have failed (Pannuti et al.
1979; Alexieva-Figusch et al. 1980; Izuo et al. 1981; Mor-
gan 1985; Muss et al. 1988; Jonat et al. 1996; Buzdar
et al. 1997, 2001; Abrams et al. 1999;). Notably, the pro-
gestin megestrol acetate was found to be efficacious in pa-
tients with ER-positive metastatic breast cancer after AI
treatment failure (Bines et al. 2014). In this single-arm
phase II trial, 48 post-menopausal women were adminis-
tered 160 mg of megestrol acetate daily (a well-tolerated
treatment yielding a clinical benefit rate of 40%), with a
median treatment duration of 10 mo. Based on preclinical
evidence, we speculate that this response to megesterol
acetate results from PR activation and sequestration of
ER binding and activity.
Most recently, the preclinical findings of functional
cross-talk between ER and PR from our laboratory have
now been translated into the clinic, driven by the hypoth-
esis that the addition of a progesterone agonist will
enhance the anti-proliferative effect of standard anti-
estrogen therapy. This is based on the paradigm that PR
activationwill influence ER binding and change the target
genes of this transcription factor (Fig. 2A). A phase II pre-
operative window study (NCT03306472) investigating
the effect of combining megestrol acetate and an AI in
post-menopausal women with early breast cancer is cur-
rently ongoing at our institute, while another ongoing
study is evaluating this combination in a cohort of pa-
tients with advanced ER+ breast cancer (NCT03024580).
In addition, two other studies in the UK and Australia us-
ing progestins in combination with ER targeting agents
are scheduled to open soon.
It is important to acknowledge that, in contrast to the
beneficial role of progestogens in breast cancer patients,
certain specific progestogens have been shown to increase
breast cancer incidence in healthy women (Hankinson
et al. 2004; Chlebowski et al. 2013; Asi et al. 2016), al-
though, importantly, this is not associated with long-
term increased risk of all-cause mortality (Manson et al.
2017). Accordingly, the mechanism underlying the role
of the PR axis in driving breast cancer risk in themamma-
ry glands has been explored extensively (Graham et al.
2009; Lydon and Edwards 2009; Hilton et al. 2015). Taken
together, while PR targeting agents in breast cancer pa-
tients remain a viable therapeutic approach (Carroll
et al. 2017), the precise mechanisms through which PR
regulates tumor compared with mammary gland prolifer-
ation warrants further exploration.
Androgen receptor (AR) In addition to PR, functional
cross-talk between ER and the AR has also been described
in breast cancer cells. ER and AR are coexpressed in 80%–
90% of ER+ breast cancer cells, and high AR expression is
associated with good outcome in ER+, but not ER−, breast
cancers (Peters et al. 2009). However, the role of AR in ER+
breast cancer is controversial, since both AR agonists and
antagonists have been suggested to inhibit growth of
breast cancer cells in preclinical models, at least partly
by inhibiting ER function (Panet-Raymond et al. 2000;
Greeve et al. 2004; Peters et al. 2009; Cochrane et al.
2014; D’Amato et al. 2016). This inhibitory effect of AR
is mediated to a certain extent through binding of ER
and AR to the same genomic regions (Need et al. 2012;
D’Amato et al. 2016). Although this clearly implicates
AR as an important steroid receptor in ER+ breast cancer,
furtherwork is needed to fully understand themechanism
through which this receptor works in breast cancer cells.
Clinically, the high level of coexpression of AR and PR
in ER+ breast cancer makes these sex steroid receptors at-
tractive targets for therapeutic intervention. Despite the
historic demonstration of therapeutic benefits seen with
androgen treatment in breast cancer (Tormey et al. 1983;
Ingle et al. 1991), the use of androgens diminished due to
Estrogen receptor cross-talk in cancer
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the virilizing adverse effects of this class of agents, con-
cerns regarding aromatization of androgens to estrogen,
and the emergence of tamoxifen and AIs as effective ther-
apies in ER+ breast cancer. However, given the resurgence
of preclinical data supporting a role of AR in ER+ breast
cancer described above, a focus on targeting of the AR sig-
naling axis in these tumors has re-emerged, with both op-
posing agonistic and antagonistic strategies. Preclinical
data suggesting a proproliferative role of AR in ER+ breast
cancer (Cochrane et al. 2014; D’Amato et al. 2016), togeth-
er with the growing evidence supporting efficacy of AR in-
hibition in AR+ triple-negative breast cancer (Bonnefoi
et al. 2016; Traina et al. 2018), have lead to ongoing combi-
nation trials using the selectiveAR inhibitor bicalutamide
(NCT02910050) and the anti-androgen enzalutamide
(NCT02953860). However, AR inhibition strategies are
likely to be limited to contexts in which AR is the driving
nuclear receptor, as seen in the AR+ triple-negative breast
cancer subtype, and the bulk of the evidence in ER+ breast
cancer supports an anti-proliferative role of androgens. In
this regard, great promise surrounds a new breed of selec-
tiveARmodulators, such as enobosarm (GTx-024). Enobo-
sarm is a potent AR agonist with reduced capacity for
androgenization and without estrogenic properties (Coss
et al. 2014). A small proof-of-concept study confirmed ac-
tivity and tolerability in a cohort of heavily pretreated
ER/AR+ patients with metastatic breast cancer (Over-
moyer et al. 2014), and results froma follow-up phase II tri-
al are awaited (NCT02463032). These recent findings
support a role for AR agonists as anti-proliferative agents
in ER+ breast cancer contexts.
Glucocorticoid receptor (GR) GR is expressed in nearly
70%of ER+ breast cancers, and highGRexpression is asso-
ciated with low tumor grade (Abduljabbar et al. 2015) and,
in some cases, has been associated with good clinical out-
come (Pan et al. 2011; West et al. 2016). Mechanistic stud-
ies inmammaryepithelial andbreast cancer cell lineshave
convincingly demonstrated that both receptors canmodu-
late chromatin binding of each other upon cotreatment
with estradiol and the synthetic glucocorticoid dexame-
thasone (Fig. 2B; Miranda et al. 2013; West et al. 2016).
This redistribution of receptor binding to chromatin oc-
curs through an assisted loading mechanism involving
chromatin remodeling byone receptor followedby recruit-
ment of the other receptor (Miranda et al. 2013). Interest-
ingly, GR-mediated redistribution of ER binding is not
dependent on ER DNA-binding capacity. Instead, tether-
ing of ER to chromatin at these sites is dependent on the
transcription factorAP-1,which is recruiteduponchroma-
tin remodeling by GR (Fig. 2B; Miranda et al. 2013). Simi-
larly, GR gets recruited indirectly to ER-binding sites
upon costimulation with the ligands for these receptors
(Fig. 2B). This occurs through a tetheringmechanism like-
ly involving a direct interaction between ER bound to its
ERE and the DNA-binding domain of GR, although the
DNA-binding capacity of GR is not required for GR re-
cruitment to these sites (Karmakar et al. 2013; Miranda
et al. 2013;West et al. 2016; Yang et al. 2017). This indirect
recruitment of GR through ER is dependent on SUMOyla-
tion of GR, and, although it does not affect binding of ER
and its pioneer factor, FOXA1, to these sites, it disrupts
binding of other well-described ER cooperating factors
such as AP2γ, GATA3, retinoic acid receptor α (RARα),
p300, and steroid receptor coactivator-3 (SRC3) (Karmakar
et al. 2013; Yang et al. 2017). Furthermore,GR recruits nu-
clear receptor corepressor (NCoR) and silencing mediator
of retinoid and thyroid hormone (SMRT) receptor core-
pressor complexes, and this further alters the balance of
coactivators and corepressors at these DNA regulatory
sites (Fig. 2B).This leads toa repressive chromatin environ-
ment, resulting in less localized enhancer transcription
from these sites (Yang et al. 2017).
Importantly, the transcriptional response to either dex-
amethasone or estradiol alone inMCF7 breast cancer cells
is changed when both steroid hormones are added togeth-
er, resulting in transcriptional changes in genes linked to
cell proliferation and differentiation (West et al. 2016). In-
terestingly, some of the genes induced by costimulation of
ER and GR were shown to inhibit cell proliferation of
MCF7 cells. Furthermore, GR binding to ER enhancers re-
presses a subset of ER target genes associated with poor
outcome in breast cancer patients (Yang et al. 2017).
This indicates that redistribution of ER and GR binding
upon costimulation with glucocorticoids and estradiol
can change the transcriptome to favor a less proliferative
phenotype. Taken together, this demonstrates extensive
genomic cross-talk between GR and ER, which is likely
to drive the anti-proliferative effect of GR and glucocorti-
coids on ER+ tumor growth.
In addition to the direct cross-talk between ER and GR
described above, GR activation can also affect tumor
growth by modulating the metabolism of estradiol
(Gong et al. 2008). GR activated by dexamethasone induc-
es expression of the sulfotransferase SULT1E1 in both
mouse livers andMCF7 breast cancer cells. SULT1E1 sul-
fonates and thereby inactivates estradiol, which results in
decreased circulating estradiol levels and, consequently,
inhibition of tumor growth in a mouse xenograft model
(Gong et al. 2008).
Clinically, glucocorticoids are used ubiquitously in
breast cancer patients in conjunction with chemotherapy
tomitigate allergic reactions and for their anti-emetic and
anti-inflammatory properties. While high tumor GR ex-
pression has been associated with a relatively poor out-
come in ER-negative breast cancer, meta-analysis of
genomic data sets has revealed that tumor GRmRNA ex-
pression is associated with improved recurrence-free sur-
vival in ER+ breast cancer, independent of PR expression
(Pan et al. 2011). Despite the preclinical finding of GR ac-
tivation reducing estrogen-induced proliferation in ER+
tumors, clinical studies have demonstrated varied effects
of glucocorticoid use on breast cancer patient survival,
with modest effects when used as a single agent and
with no effect in combination with other drugs, including
anti-estrogens in ER+ breast cancer patients (Keith 2008;
Lietzen et al. 2014). However, given the in vitro evidence
for an inhibitory effect of glucocorticoids on ER function
and breast cancer cell proliferation (Fig. 2B) together
with the proven role of glucocorticoids in AR-driven
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prostate cancer (Kach et al. 2015) and the widespread use
of glucocorticoids in the supportive care of breast cancer
patients, we feel that investigation of the full therapeutic
potential of glucorticoids still needs to be explored.
Discussion
Seventy-five percent of breast cancers are driven by the
steroid receptor ER, which is regulated by estrogenic hor-
mones. Here, we discussed the link between the function
of ER in tumor cells and signaling pathways triggered by
other steroid hormones, cytokines, and growth factors,
many of which originate from the many different cell
types surrounding the cancer cells in the tumor microen-
vironment. It is clear that in addition to activation by clas-
sic estrogenic ligands, there are at least two levels of
regulation of ER. First, chromatin binding and activity of
ER can be regulated by phosphorylation in the absence
of estrogens. Particularly, phosphorylation of S118 and
S305 appears to be important for this estrogen-indepen-
dent activation of ER, and several growth factor (e.g.,
EGF) and cytokine (e.g., TNFα) pathways can induce phos-
phorylation of these sites on ER. In addition, once ER is on
chromatin, other transcription factors can redirect the ge-
nomic binding of ER, essentially reprogramming the tran-
scriptional activity of ER to other target genes. The
transcription factors that function downstream from cyto-
kine signaling (e.g., NF-κB) and other steroid hormone re-
ceptors (e.g., PR) play important roles in regulating where
in the genome ER binds.
The fact that multiple pathways triggered by signals
from the tumor microenvironment impact ER function
and have been linked to endocrine resistance clearly high-
lights the importance of paracrine signaling for tumor pro-
gression. This emphasizes the need to further explore the
clinical potential of targeting tumor-extrinsic factors in
the microenvironment in ER+ breast cancer. However,
most of the mechanisms described above are based on in
vitro experiments, and validation of these mechanisms
in disease-relevant preclinical models (e.g., mouse xeno-
graft models and patient-derived xenografts) and patient
samples is critical in order to determine whether these
pathways may provide clinical benefit to patients. In this
regard, it is interesting to note the recent use of intraductal
injections of human cancer cells into the mouse mamma-
ry gland to establish xenograft models from cell lines and
patient samples (Sflomos et al. 2016). This method more
accurately recapitulates the tumor progression observed
in patients, with the development of metastases in organs
such as the liver, lungs, brain, and bone.This is likely to in-
crease the translatability of preclinical findings in the fu-
ture. In addition to xenograft models, tumor explant
methods that allow investigations of drug responses in pa-
tient samples (Centenera et al. 2012, 2013) are a powerful
way to investigate the potential therapeutic impact of pre-
clinical findings, as demonstrated for PR agonists (Mo-
hammed et al. 2015). Validating mechanistic findings in
preclinical models such as these is crucial to ensure trans-
latability of the wealth of mechanistic in vitro findings.
It is particularly interesting to note the high degree of
cross-talk between the different steroid receptors on chro-
matin. This group of transcription factors is highly target-
able by small molecules, and numerous agonists and
antagonists for these receptors are already Food and
Drug Administration-approved, thereby significantly
shortening the time from preclinical discoveries to clini-
cal testing. In support of this is the rapid translation of
findings linking PR agonists to ER function,with two clin-
ical trials initiated (NCT03306472 and NCT03024580)
and two more in development within 2 yr of publication
of the biological discovery.
In conclusion, ER function and therefore breast cancer
progression are directly modulated by both tumor-intrin-
sic and tumor-extrinsic factors, and many of the latter
are promising candidates for targeted therapy aimed at im-
proving survival for ER+ breast cancer patients.
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